High accuracy stool biomarkers of pre-cancerous colorectal cancer identified using a 2000-plex immunoproteomic screen.

Background: Given the morbidity and mortality associated with colorectal cancer, novel biomarkers are clearly warranted, especially for early detection METHOD: An antibody-based screen of 2000 proteins was utilized to identify stool proteins that were elevated in patients with CRC, compared to healthy controls (HCs). 37 lead candidates were selected for ELISA validation in three independent cohorts comprised of CRC patients, advanced adenoma patients, and healthy controls, drawn from two different ethnicities.

Results: Of the 2000 proteins interrogated, 116 were differentially expressed in CRC stool, with 45 being elevated at 2-fold or higher; 37 of these proteins were selected for ELISA validation in 3 independent patient cohorts. Stool MMP-8, MMP-9, Hemoglobin, PGRP-S, Haptoglobin, and Fibrinogen emerged as being most discriminatory for distinguishing CRC from healthy controls (AUC: 0.91-0.95), across cohorts and ethnicities, with several of these being significantly higher in more advanced stages of CRC. Stool Fibrinogen, MMP-9, Hemoglobin, MMP-8, and PGRP-S were the top 5 stool proteins with the highest accuracy for distinguishing advanced adenoma from HC, with stool Fibrinogen topping the list with a diagnostic accuracy of 0.86. Functional pathway analysis revealed a significant over-representation of pathways related to anti-oxidant activity, integrin/receptor binding, cytokines, blood coagulation, and lipoprotein biosynthesis in patients with CRC compared to HC. Nuclear Factor IC (NFIC) and IKZF2 were identified as key regulators of the molecular cascades over-represented in CRC.

Conclusion: Stool Fibrinogen, MMP-8, MMP-9, PGRP-S, Haptoglobin, and Myeloperoxidase emerge as promising biomarkers for distinguishing CRC/advanced adenomas/healthy stools, meeting or outperforming current yardsticks.